anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Helicobacter pylori, one of the world's most prevalent pathogens, is a spiral-shaped, catalase-positive, Gram-negative rod with 4-6 sheathed flagella attached to one pole which allow for motility. The prevalence of H. pylori infection in humans is high; 50% of those over the age of 60 are infected. H. pylori infection causes chronic gastric inflammation, ulcer disease and gastric carcinoma. Further, chronic antigenic stimulation driven by H. pylori infection has been linked to the development of gastric mucosa associated lymphoid tissue (MALT) lymphoma. Infection with H. pylori induces a vigorous immune response resulting in the presence of local and systemic antibodies. H. pylori-specific immunoglobulin G antibodies present in serum, plasma, whole blood, saliva, gastric juice and urine have each been used to successfully detect the presence of infection in adults. The sensitivity and specificity of serological tests range from 80% to 95% depending upon the assay used. H. Pylori infection is characteristically associated with a vigorous inflammatory response and we have recently identified H. Pylori DNA in conjunctival MALT lymphoma using molecular diagnostic techniques. Ocular surface inflammation is a cardinal feature of keratoconjunctivitis sicca. Since we identified H. Pylori DNA in conjunctival MALT lymphoma we hypothesize that chronic infection may also be capable of triggering chronic ocular surface inflammation as seen in keratoconjunctivitis sicca. The purpose of this pilot study is to determine whether H. pylori DNA is detectable in the conjunctiva of seropositive KCS patients.
Well-being of caregivers and stress management in intensive care units are essential keys to an adequate quality of care, especially during the anxious context of coronavirus pandemic. Taking care of numerous patients, the increasing work and mental charges, facing death, the need of material and changes in work organization are all elements that can influence stress among medical workers. Considering real causes of stress and what are the needs of the medical team is fundamental for developing concrete actions to ease the workloads. A few studies were conducted in China on psychological distress of medical staff during COVID-19. According to these few studies about psychological distress in ICU, investigators think that stress scores during COVID-19 could be increased among nurses during pandemic. The second hypothesis is that causes of stress would be not so different from normal care but could be amplified by the actual situation. One point to take into consideration is that most of the studies were conducted in China and medical policy and hospital organization are different in Belgium. The objective of the study is to compare psychological distress and needs of nurses in ICU before and during coronavirus pandemic.
PURPOSE: Multimodal imaging was performed to characterize butterfly hair-induced keratitis based on anterior segment optical coherence tomography and in vivo confocal microscopy.
METHODS: This study was a case report.
RESULTS: A 6-year-old girl presented with acute keratitis induced by multiple butterfly hairs. Severe itching and pain developed immediately after rubbing her left eye, leading to significant pain and moderate vision loss, even after undergoing twice removal of the corneal epithelium. The hair-like foreign bodies were distributed at various depths inside the corneal stroma, even extending into the anterior chamber. The symptoms and corneal infiltration gradually decreased within 6 months with the use of topical steroids and immunosuppressors. The hairs located in the superficial and middle stromal layers of the cornea disappeared at the 6-month follow-up, but the hairs in the deep stromal layer tended to move deeper. The diagnosis was confirmed by in vivo confocal microscopy and microphotography. The migration tendency of the hairs into the intraocular space was observed using anterior segment optical coherence tomography (AS-OCT).
CONCLUSIONS: Butterfly hair-induced keratitis can be controlled by the treatment with topical steroids and immunosuppressors, but the hairs tend to move into the eyes. To the best of our knowledge, this is the first case of corneal in vivo confocal imaging of butterfly hairs.
Group B participants will be prescribed bisacodyl rectal (Dulcolax Suppository; Sanofi S.A., Paris, France) 1 suppository to be placed rectally on the morning of Post Operative Day (POD)#1. Participant will continue placing a nightly rectal suppository until their first bowel movement. If no bowel movement by the morning of POD#5 participant may take magnesium hydroxide (Phillips' Milk of Magnesia; Bayer AG, Leverkusen, Germany) 30 mL by mouth and need to call the clinic for further instruction.
Dipilatory compositions in aerosol form comprise butane as propellant and a dipilatory composition comprising lithium ions and anions of thioglycollic or a - or b -mercaptopropionic acid having a pH of 13 or less.  Hair-swelling agents e.g. urea, thiourea, melamine, guanidine or an alkali metal cyanate or a water-insoluble alkaline earth metal salt, e.g. CaCO3 may also be present.ALSO:Depilatory compositions comprise lithium cations and thioglycollic acid or a - or b -mercaptopropionic acid anions. The compositions have a pH of 13 or less and may be in the form of a cream or lotion and may be packaged in an aerosol container with a propellant, e.g. butane.  A hair-swelling agent e.g. urea, thiourea, melamine, geranidine or an alkali metal cyanate and a water-insoluble alkaline earth metal inorganic salt e.g. CaCO3 may also be present.
Patients receive panobinostat PO QD on days 1, 3, 5, 15, 17, 19, daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles, bortezomib SC on days 1, 8, 15, 22 and dexamethasone PO (IV on days of daratumumab and hyaluronidase-fihj administration) QD on days 1, 8, 15, 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Participants receive tamoxifen PO QD and omega-3 fatty acids PO BID for 180 days in the absence of unacceptable toxicity. Participants may continue to receive tamoxifen PO QD and omega-3 fatty acids PO BID for up to 60 additional days in the case of scheduling delays. Participants also undergo mammography at screening and undergo RPFNA and collection of blood samples at screening and on study.
The present disclosure belongs to the technical field of biology and relates to a recombinant adeno—associated, virus vector, a recombinant adeno—associated virus and use thereof. The recombinant adeno—associated virus vector is formed by inserting a 5 nucleotide sequence of a PD—l extracellular segment into an adeno— associated virus vector, wherein the nucleotide sequence of a PD—l extracellular segment is as shown in SEQ ID NO: 1. According to the recombinant adeno—associated virus vector provided by the present disclosure, an extracellular segment (a total of 170 amino 10 acids) of PDl is inserted into an adeno—associated virus AAV8 for expression and soluble PDl is secreted. Therefore, the soluble PDl can bind to PDLl on tumor cells, a PD—l/PD—Ll signaling pathway is effectively blocked, and the PDLl on the tumor cells is prevented from binding to the PDl on T cells to avoid exhaustion of the T 15 cells. (+ Fig. 1)
Methods and systems for managing healthcare quality measure data are provided. Relevant quality measure data relating to a patient with a particular condition is identified, and it is determined if patient qualifies for a standardized quality measure related to that condition. If the patient qualifies, the relevant quality measure data is populated into a work queue associated with a computing device and displayed to a user. The relevant quality measure may be approved and sent to a quality clearinghouse. If the relevant quality measure data is not approved, additions, deletions, or changes are made to generate a revised set of relevant quality measure data which is then sent to the quality clearinghouse. The approved relevant quality measure data is received by the quality clearinghouse, and a recipient is selected to receive the relevant quality measure data. The relevant quality measure data is reformatted to the specifications of the recipient and is sent to the recipient.
FIELD: dairy industry.SUBSTANCE: method for obtaining modified micellar casein concentrate is carried out in the following way. The volume of skimmed milk is provided and used. The process of microfiltration of the volume of skimmed milk is performed to obtain micellar casein concentrate. Micellar casein concentrate is treated with carbon dioxide by mixing carbon dioxide with at least part of micellar casein concentrate to reduce pH of micellar casein concentrate and acidify micellar concentrate and to solubilize one or more components of micellar casein concentrate. The mixture of carbon dioxide and micellar casein concentrate is ultrafiltered to remove at least one or more solubilized components of micellar casein concentrate to obtain modified micellar casein concentrate. Options of the method for obtaining micellar casein concentrate with a modified mass fraction of fat are proposed.EFFECT: group of inventions provides a reduction in the content of mineral substances in the concentrate by 5-40% compared to conventional membrane filtration approaches, while maintaining a high level of protein.16 cl, 11 dwg, 3 tbl
Thirty-eight adult men and women with DM2 will be recruited from the University of Minnesota and surrounding communities, and will be randomized to treatment with the LoBAG diet or a control diet. Following a consent and screening visit, there will be 5 additional study visits over a 12-week diet intervention period. Instruction in the assigned diet will be provided by a research dietitian at the beginning of the 12-week period, and reinforced at subsequent visits throughout the study. Participants will be asked to purchase food, prepare food, and consume the assigned diet in their own homes. They will be asked to keep activity level constant and to continue medications for diabetes (metformin or no medication) without change during the intervention. The primary outcome, HgbA1c, and secondary outcome measures will be assessed at baseline and following diet intervention. Study visits will occur at baseline (visits 1 and 2), week 1 (visit 3), week 6 (visit 4), week 9 (visit 5) and week 12 (final study visit). In addition to scheduled study visits the research team will contact participants every other week by telephone to address any issues that arise, with the purpose of increasing compliance and retention. Participants will be contacted once in weeks 9-12 for a 24-hour diet recall collected by the Nutrition Coordinating Center at the University of Minnesota. Study procedures will conclude after the 12-week diet intervention period and collection of all outcome measures.
FIELD: experimental and clinical hematology, immunology, oncology, radiation medicine. SUBSTANCE: invention proposes the use of synthetic polypeptide as a growth stimulating agent of bone marrow cells. Peptide has the following sequence of amino acids: lysine-glycine-proline-leucine-threonine-norleucine- norleucine-alanine-serine-histidine-tyrosine-lysine-glycine- histidine-cysteine-proline of the formula Lys-Gly-Pro-Leu-Thr- -Nle-Nle-Ala-Ser-His-Tyr-Lys-Gly-His-Cys-Pro. PPO corresponding to the natural GM-KSF molecule site. Proposed peptide is synthesized by solid-phase method. Stimulating agent provides treatment without adverse effects and complications. EFFECT: enhanced effectiveness of the agent. 1 cl, 1 tbl, 1 ex
The placebo arm will self-administer a subcutaneous injection of placebo. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will receive an injection of placebo 120 mg. The injections will be with a pre-loaded syringe containing placebo.
Inherited metabolic epilepsies (IMEs) represent inherited metabolic disorders predominately presenting with seizures. While most IMEs are currently managed with symptomatic and supportive therapies, some are amenable to disorder-specific targeted treatments. In most cases, these treatments are effective only if given in a narrow time window early in the lives of affected patients. Hence, prompt recognition of treatable inherited metabolic epilepsies at an early age and as soon as symptoms appear has paramount importance. Herein, we provide an overview of inherited metabolic epilepsies, which presently have established targeted treatments showing clinical efficacy in reducing seizure burden and improving neurodevelopmental outcomes. These therapeutic modalities range from specific diets, vitamins, and supplementation of organic compounds to synthetic pharmacological agents and novel genetic-based therapies that alter the biochemical pathways of these disorders at the cellular or molecular level, steering them to their normal function.
Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis. Placebo capsules will be similarly dosed at 4 capsules daily.
Qualitative study retrospective research interviews with the doctor and another carer involved in the care of the patient, and close relatives of patients who had sedated before their death. The interviews will be based on 50 cases of patients who have been sedated.
As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe congestive heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme inhibitors, including lisinopril, may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death.

In hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine may occur. Experience with another angiotensin-converting enzyme inhibitor suggests that these increases are usually reversible upon discontinuation of lisinopril and/or diuretic therapy. In such patients renal function should be monitored during the first few weeks of therapy.

Some hypertensive patients with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when lisinopril has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction of lisinopril and/or discontinuation of the diuretic may be required.

Evaluation of the hypertensive patient should always include assessment of renal function. (SeeDOSAGE AND ADMINISTRATION.)
Nasopharyngeal cancer (NPC) is a cancer that starts at the back of the nose. Without distant spread, NPC is sensitive to radiotherapy and chemotherapy. However, the treatment of this cancer can lead to later complications, including other cancers, and if NPC relapses or spreads to other organs, the treatment options are limited. This grant proposes to evaluate the safety and tolerability of a novel treatment for patients with NPC that has either relapsed or spread to distant organs.

Epstein-Barr Virus (EBV) is known to play a role in the development of NPC in individuals, especially those with a compromised immune system. Studies have shown that NPC tumor cells express proteins that are related to EBV. Some of these proteins can trigger a response from the immune system, specifically the activation of cytotoxic T lymphocytes (CTLs), a type of immune cell that might exert anti-tumor effects. In this project, we will take blood from NPC patients, generate CTLs targeted against EBV, and re-infuse these back into patients in an attempt to achieve anti-tumor activity. Patients will also receive an antibody called CD45 Mab prior to CTL infusion in order to allow for better expansion of the infused CTLs in the patients.
We present the case of an elderly man with a history of diastolic congestive heart failure, severe aortic stenosis and atrial fibrillation, who presented with fatigue, weakness, coffee ground emesis and black tarry stool. Haemoglobin was 68 g/L. Lactate dehydrogenase was elevated at 1038. Evaluation by cardiology and gastroenterology specialists revealed reflux oesophagitis and a mild hiatal hernia on oesophagogastroduodenoscopy, normal colonoscopy and small bowel series without obstruction. Capsule endoscopy identified angiodysplasia in the small intestine.The patient was diagnosed with Heyde's syndrome based on the triad of severe aortic stenosis, gastrointestinal bleeding from angiodysplasia and acquired von Willebrand syndrome. The patient underwent transcatheter aortic valve replacement, resulting in the resolution of symptoms.Heyde's syndrome represents a challenging clinical entity requiring a multidisciplinary approach for accurate diagnosis and management. Early recognition, prompt intervention and interdisciplinary collaboration are crucial in optimising patient outcomes.
In the monotherapy study, hallucinations were reported as an adverse event in 1.3% of patients treated with 1 mg rasagiline and in 0.7% of patients treated with placebo. In the monotherapy trial, hallucinations led to drug discontinuation and premature withdrawal from clinical trials in 1.3% of the 1 mg rasagiline-treated patients and in none of the placebo-treated patients.

When used as an adjunct to levodopa, hallucinations were reported as an adverse reaction in approximately 5% of patients treated with 0.5 mg/day AZILECT, 4% of patients treated with 1 mg/day AZILECT and 3% of patients treated with placebo. Hallucinations led to drug discontinuation and premature withdrawal from clinical trials in about 1% of patients treated with 0.5 mg/day or 1 mg/day rasagiline and none of the placebo-treated patients.

Patients should be informed of the possibility of developing hallucinations and instructed to report them to their health care provider promptly should they develop.

Patients with a major psychotic disorder should ordinarily not be treated with AZILECT because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone. In addition, many treatments for psychosis that decrease in central dopaminergic tone may decrease the effectiveness of AZILECT. 

AZILECT administration may cause or exacerbate psychotic-like behavior based upon post-marketing reports. This adverse reaction has been reported with many anti-Parkinsonian drugs that increase central dopaminergic tone. This abnormal behavior has been exhibited by one or more of a variety of manifestations including paranoia, confusional state/confusion, psychotic disorder, agitation, delusion, and hallucinations.
The present invention relates to an oral disintegration tablet and a preparation method thereof. The oral disintegration tablet comprises medicinal active components and auxiliary materials, wherein the auxiliary material comprises a diluting agent and a disintegrating agent. The diluting agent is mannitol and lactose, and the disintegrating agent is microcrystalline cellulose, low-substituted hydroxypropyl cellulose and cross-linked polyvinylpyrrolidone. The weight of the disintegrating agent is less than 25% of the total amount of the auxiliary materials. The weight ratio of the medicinal active components to the auxiliary materials is 1:2 to 75. The weight ratio of the mannitol to the lactose is 1.8 to 5:1. The proportion of the microcrystalline cellulose and the low-substituted hydroxypropyl cellulose is 4 to 5:1, and the proportion of the microcrystalline cellulose and the low-substituted hydroxypropyl and the cross-linked polyvinylpyrrolidone is 1:0.37 to 0.67. The oral disintegration tablet provided by the present invention has enough hardness (strength), which can meet the requirements of production, packaging, storage and transportation. Simultaneously, the oral disintegration tablet has favorable taste and short disintegration time. The oral disintegration tablet can be prepared by ordinary pressing equipment and a simple technology.
Sinonasal squamous cell carcinoma (SNSCC) is an aggressive cancer affecting the nasal and sinus regions, with its progression factors, particularly genetic ones, not yet fully understood. Here, we first conducted a retrospective study with 219 SNSCC patients to identify clinical factors affecting SNSCC prognosis. Additionally, we mined a vast literature dataset to uncover genetic factors associated with SNSCC progression. Based on this data, we constructed SNSCC prognosis pathways and performed a gene set enrichment analysis (GSEA). Clear operative margins were linked to a 73.5-86.3% improvement in overall survival and a 73.5-88.9% lower risk of recurrence. Nasal cavity-originated cases exhibited a 67.6-97.4% decrease in mortality and an 80.7-96.7% lower recurrence rate. Patients at T1-2 staging had a 65.0-80.6% reduced risk of death and recurrence compared to those at T3 stage. Additionally, we identified 53 genes associated with SNSCC, with 14 also implicated in primary tumor site, T stage, and operative margin. These genes, including EGFR, PIK3CA, ERBB2, PTEN, BCL2, BRAF, KRAS, and PRL, form a complex SNSCC-prognosis pathway and were significantly enriched in 42 KEGG pathways and Gene Ontology (GO) terms (FDR-corrected p-value < 0.001), influencing cell growth, apoptosis, and oncogenic signaling pathways. Our study suggests that three clinical parameters (operative margin type, primary tumor site, and T-stage) and 14 genetic factors may influence SNSCC prognosis post-surgery. These findings deepen our understanding of SNSCC and offer potential avenues to enhance its treatment and outcomes.
BYDUREON BCISE (exenatide) extended-release injectable suspension is a GLP-1 receptor agonist supplied as a sterile suspension of exenatide extended-release microspheres in an oil-based vehicle of medium chain triglycerides (MCT), in a single-dose autoinjector. Redispersion by mixing provides a white to off-white, opaque, suspension to be administered by subcutaneous injection. Each autoinjector contains sufficient suspension to deliver 2 mg of exenatide extended-release in a volume of 0.85 mL.

Exenatide is a 39-amino acid synthetic peptide amide with an empirical formula of C184H282N50O60S and a molecular weight of 4186.6 Daltons. The amino acid sequence for exenatide is shown below.

H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Exenatide is incorporated in an extended-release microsphere formulation containing the 50:50 poly (D,L-lactide-co-glycolide) polymer (37.2 mg per dose) along with sucrose (0.8 mg per dose), suspended in the vehicle, MCT (774.4 mg per dose).